Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein

Human Gene Therapy

Volumn 16, Issue 2, 2005, Pages 187-199

  Wang, Yu ^a   Xu, Minzhen ^b   Che, Mingxin ^a   Von Hofe, Eric ^b   Abbas, Asad ^a   Kallinteris, Nikoletta L ^b   Lu, Xueqing ^b   Liss, Zachary J ^a   Forman, Jeffrey D ^a   Hillman, Gilda G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Subsidiary Generex Biotech Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARRIER PROTEIN; COMPLEMENTARY DNA; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 TRANSACTIVATOR; MEMBRANE PROTEIN; PROTEIN II; PROTEIN II REVERSE GENE CONSTRUCT; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CELL INFILTRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE INDUCTION; GENE THERAPY; GENETIC TRANSFECTION; HELPER CELL; IMMUNE RESPONSE; INFLAMMATORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PROSTATE CARCINOMA;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; X-RAYS;

ANIMALIA; MURINAE;

EID: 20044366545     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.187     Document Type: Article

References (38)

1. ARMSTRONG, T.D., CLEMENTS, V.K., MARTIN, B.K., TING, J., and OSTRAND-ROSENBERG, S. (1997). Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. U.S.A. 94, 6886-6891.
2. ARMSTRONG, T.D., CLEMENTS, V.K., and OSTRAND-ROSENBERG, S. (1998a). MHC Class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J. Immunol. 160, 661-666.
3. ARMSTRONG, T.D., CLEMENTS, V.K., and OSTRAND-ROSENBERG, S. (1998b). Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J. Immunother. 21, 218-224.
4. BELLDEGRUN, A., TSO, C.L., ZISMAN, A., NAITOH, J., SAID, J., PANTUCK, A.J., HINKEL, A., DEKERNION, J., and FIGLIN, R. (2001). Interleukin 2 gene therapy for prostate cancer: Phase 1 clinical trial and basic biology. Hum. Gene Ther. 12, 883-892.
5. CLEMENTS, V.K., BASKAR, S., ARMSTRONG, T.D., and OSTRAND-ROSENBERG, S. (1992). Invariant chain alters the malignant phenotype of MHC class II tumor cells. J. Immunol. 149, 2391-2396.
6. DEZSO, B., HAAS, G.P., HAMZAVI, F., KIM, S., MONTECILLO, E.J., BENSON, P.D., PONTES, J.E., MAUGHAN, R.L., and HILLMAN, G.G. (1996). Insights into the mechanism of local tumor irradiation combined with IL-2 therapy in murine renal carcinoma: Histological evaluation of pulmonary metastases. Clin. Cancer Res. 2, 1543-1552.
7. FORMAN, J.D., TEKYI-MENSAH, S., CAUDRELIER, J.M., FALQUEZ, R., VELASCO, J., PORTER, A.T., and MAUGHAN, R.L. (1998). Neutron radiation in the management of localized and locally advanced prostate cancer. In Advances in the Radiotherapeutic Management of Carcinoma of the Prostate. A.V. D'Amico and G.E. Hanks, eds. (Chapman and Hall, New York, NY).
8. GRAY, C.L., POWELL, C.R., RIFFENBURGH, R.H., and JOHNSTONE, P.A. (2001). 20-year outcome of patients with T1-3N0 surgically staged prostate cancer treated with external beam radiation therapy. J. Urol. 166, 116-1 18.
9. GRIFFITH, T.S., KAWAKITA, M., TIAN, J., RITCHEY, J., TARTAGLIA, J., SEHGAL, I., THOMPSON, T.C., ZHAO, W., and RATLIFF, T.L. (2001). Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J. Natl. Cancer Inst. 93, 998-1007.
10. GUAGLIARDI, L.E., KOPPELMAN, B., BLUM, J.S., MARKS, M.S., CRESSWELL, P., and BRODSKY, F.M. (1990). Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. Nature 343, 133-139.
11. HALL, S.J., MUTCHNIK, S.E., CHEN, S., WOO, S., and THOMPSON, T.C. (1997). Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int. J. Cancer 70, 183-187.
12. HARRINGTON, K.J., SPITZWEG, C., BATEMAN, A.R., MORRIS, J.C., and VILE, R.G. (2001). Gene therapy for prostate cancer: Current status and future prospects. J. Urol. 166, 1220-1233.
13. HILLMAN, G.G., TRIEST, J.A., CHER, M.L., KOCHERIL, S.V., and TALATI, B.R. (1999). Prospects of immunotherapy for the treatment of prostate carcinoma-A review. Cancer Detect. Prev. 23, 333-342.
14. HILLMAN, G.G., MAUGHAN, R.L., GRIGNON, D.J., YUDELEV, M., RUBIO, J., TEKYT-MENSAH, S., LAYER, A., CHE, M., and FORMAN, J.D. (2001). Neutron or photon irradiation for prostate tumors: Enhancement of cytokine therapy in a metastatic tumor model. Clin. Cancer Res. 7, 136-144.
15. HILLMAN, G.G., KALLINTERIS, N.L., LI, J., WANG, Y., LU, X., LI, Y., WU, S., WRIGHT, J.L., SLOS, P., GULFO, J.V., HUMPHREYS, R.E., and XU, M. (2003a). Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther. 10, 1512-1518.
16. HILLMAN, G.G., XU, M., WANG, Y., WRIGHT, J.L., LU, X., KALLINTERIS, N.L., TEKYI-MENSAH, S., THOMPSON, T.C., MITCHELL, M.S., and FORMAN, J.D. (2003b). Radiation improves intratumoral gene therapy for induction of cancer vaccine in murine prostate carcinoma. Hum. Gene Ther. 14, 763-775.
17. HILLMAN, G.G., KALLINTERIS, N.L., LU, X., WANG, Y., WRIGHT, J.L., LI, Y., WU, S., FORMAN, J.D., GULFO, J.V., HUMPHREYS, R.E., and XU, M. (2004a). Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat. Rev. 30, 281-290.
18. HILLMAN, G.G., SLOS, P., WANG, Y., WRIGHT, J.L., LAYER, A., DE MEYER, M., YUDELEV, M., CHE, M., and FORMAN, J.D. (2004b). Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. Cancer Gene Ther. 11, 61-72.
19. KIM, J.J., YANG, J.S., DANG, K., MANSON, K.H., and WEINER, D.B. (2001). Engineering enhancement of immune responses to DNA-based vaccines in a prostate cancer model in rhesus macaques through the use of cytokine gene adjuvants. Clin. Cancer Res. 7, 882s-889s.
20. KOCH, N., KOCH, S., and HAMMERLING, G.J. (1982). Ia invariant chain detected on lymphocyte surfaces by monoclonal antibody. Nature 299, 644-645.
21. LU, X., KALLINTERIS, N.L., LI, J., WU, S., LI, Y., JIANG, Z., HILLMAN, G.G., GULFO, J.V., HUMPHREYS, R.E., and XU, M. (2003). Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol. Immunother. 52, 592-598.
22. NASU, Y., BANGMA, C.H., HULL, G.W., LEE, H.M., HU, J., WANG, J., MCCURDY, M.A., SHIMURA, S., YANG, G., TIMME, T.L., and THOMPSON. T.C. (1999). Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 6, 338-345.
23. OSTRAND-ROSENBERG, S., THAKUR, A., and CLEMENTS, V. (1990). Rejection of mouse sarcoma cells after transfection in MHC class 11 genes. J. Immunol. 144, 4068-4071.
24. POWELL, C.R., HUISMAN, T.K., RIFFENBURGH, R.H., SAUNDERS, E.L., BETHEL, K.J., and JOHNSTONE, P.A. (1997). Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J. Urol 157, 1754-1759.
25. QI, L., ROJAS, J.M. and OSTRAND-ROSENBERG, S. (2000). Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J. Immunol. 165, 5451-5461.
26. SAFFRAN, D.C., HORTON, H.M., YANKAUCKAS, M.A., ANDERSON, D., BARNHART, K.M., ABAI, A.M., HOBART, P., MANTHORPE, M., NORMAN, J.A. and PARKER, S.E. (1998). Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: Induction of CD8+ T-cell immunity. Cancer Gene Ther. 5, 321-330.
27. SIMONS, J.W., MIKHAK, B., CHANG, J.F., DEMARZO. A.M., CARDUCCI, M.A., LIM, M., WEBER. C.E., BACCALA, A.A., GOEMANN, M.A., CLIFT, S.M., ANDO, D.O., LEVITSKY, H.I., COHEN, L.K., SANDA, M.G., MULLIGAN, R.C., PARTIN, A.W., CARTER, H.B., PIANTADOSI, S., MARSHALL, F.F., and NELSON, W.G. (1999). Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168.
28. STEINER, M.S., and GINGRICH, J.R. (2000). Gene therapy for prostate cancer: Where are we now? J. Urol. 164, 1121-1136.
29. STEVENS, C.W., ZENG, M., and CERNIGLIA, G.J. (1996). Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum. Gene Ther. 7, 1727-1734.
30. STOCKINGER, B., PESSARA, U., LIN. R., HABICHT, J., GREZ, M., and KOCH, N. (1989). A role of la-associated invariant chains in antigen processing and presentation. Cell 56, 683.
31. TEH, B.S., AGUILAR-CORDOVA, E., KERNEN, K., CHOU, C.C., SHALEV, M., VLACHAKI, M.T., MILES, B., KADMON, D., MAI, W.Y., CAILLOUET, J., DAVIS, M., AYALA, G., WHEELER, T., BRADY, J., CARPENTER, L.S., LU, H.H., CHIU, J.K., WOO, S.Y., THOMPSON, T., and BUTLER, E.B. (2001). Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-A preliminary report. Int. J. Radial. Oncol. Biol. Phys. 51, 605-613.
32. THOMPSON, T.C., SOUTHGATE, J., KITCHENER, G., and LAND, H. (1989). Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted model. Cell 56, 917-930.
33. TRUDEL, S., TRACHTENBERG, J., TOI, A., SWEET, J., LI, Z.H., JEWETT, M., TSHILIAS, J., ZHUANG, L.H., HITT, M., WAN, Y., GAULDIE, J., GRAHAM, F.L., DANCEY, J., and STEWART, A.K. (2003). A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 10, 755-763.
34. XU, M., QIA, G., VON HOFE, E., and HUMPHREYS, R.E. (2000). Genetic modulation of tumor antigen presentation. Trends Biotechnol. 18, 167-172.
35. XU, M., LU, X., KALLINTERIS, N.L., WANG, Y., WU, S., VON HOFE, E., GULFO, JV., HUMPHREYS, R.E., and HILLMAN, G.G. (2004). Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr. Opin. Mol. Ther. 6, 160-165.
36. YOUNES, E., HAAS, G.P., DEZSO, B., ALL E., MAUGHAN, R.L., KUKURUGA, M.A., MONTECILLO, E.J., PONTES, J.E., and HILLMAN, G.G. (1995). Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell. Immunol. 165, 243-251.
37. ZENG, M., CERNIGLIA, G.J., ECK, S.L., and STEVENS, C.W. (1997). High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum. Gene Ther. 8, 1025-1032.
38. ZHANG, M., LI, S., LI, J., ENSMINGER, W.D., and LAWRENCE, T.S. (2003). Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol. Ther. 8, 21-28.